Add BrightSurf on Google Email

NIH/National Institute of Allergy and Infectious Diseases


Study Confirms That Combination Treatment Using A Protease Inhibitor Can Delay HIV Disease Progression And Death

A recent NIH study found that a combination of a protease inhibitor and two nucleoside analogue reverse transcriptase inhibitors can significantly reduce the occurrence of AIDS-defining illnesses or death. The study, ACTG 320, demonstrated improved survival and delayed disease progression in patients receiving triple combination therapy.